


**Online Resource 3.** Analysis of time to first outcome of composite renal endpoints, including death, in the patients in the effectiveness analysis set with available Hb levels at 3 months after the start of darbepoetin administration were stratified by Hb <11 g/dL or  $\geq$ 11 g/dL.

(a) All patients.

(b) Patients whose baseline Hb levels were <11 g/dL. Composite renal endpoints: 50% reduction in eGFR, initiation of dialysis, kidney transplantation, or death.


Abbreviations: eGFR, estimated glomerular filtration rate; Hb, hemoglobin

# Online Resource 3a.



Number at risk	
Hb level at 3 months of treatment: <11 g/dL	2380   2380   1988   1331   653   48
Hb level at 3 months of treatment: >=11 g/dL	1093   1093   950   711   413   31

# Online Resource 3b.



Number at risk						
	Start	0.25	0.5	1	2	3
Hb level at 3 months of treatment: <11 g/dL	2147	2147	1793	1194	588	41
Hb level at 3 months of treatment: >=11 g/dL	818	818	699	498	278	20